Journal of Immunology Research

Research Article

Polymorphisms CYP2R1 rs10766197 and CYP27B1 rs10877012 in Multiple Sclerosis: A Case-Control Study

Table 3

Comparison of clinical and genetic characteristics between severe progression and low progression in multiple sclerosis patients.
VariableSevere progression
()
Low progression
()
Female, (%)25 (64.1)51 (66.2)0.98
Age, (years)36 (19-59)40 (19-66)0.13
Disease characteristics
 Disease evolution, (years)3 (1-9)12 (2-28)<0.001
 EDSS, (score)4.0 (1-7)2.5 (0-7)0.008
Serum 25(OH) vitamin D levels, (ng/mL)15.7 (3.8-50.9)16.4 (5.4-45.3)0.88
 Sufficient (>30 ng/mL), (%)4 (10.3)13 (16.9)
 Insufficient (20-30 ng/mL), (%)12 (30.7)9 (11.7)0.037
 Deficient (<20 ng/mL), (%)23 (59.0)55 (71.4)
Treatment
 Glatiramer acetate, (%)9 (23.1)30 (39.0)0.10
 Interferon, (%)7 (17.9)20 (25.9)0.36
 Rituximab, (%)9 (23.1)3 (3.9)0.003
 Fingolimod, (%)3 (7.7)8 (10.4)0.75
 Dimethyl fumarate, (%)4 (10.3)3 (3.9)0.22
 Azathioprine, (%)3 (7.7)2 (2.6)0.33
 Natalizumab, (%)1 (2.5)3 (3.9)1.00
No treatment, (%)3 (7.7)8 (10.4)0.49
Genetic characteristics
rs10766197, CYP2R1 gene
Genotypes
 GG, (%)12 (30.8)31 (40.3)
 GA, (%)21 (53.8)37 (48.0)0.58
 AA, (%)6 (15.4)9 (11.7)
Allele
 A, (%)33 (42.3)55 (35.7)0.33
 G, (%)45 (57.7)99 (64.3)0.33
rs10877012, CYP2B1 gene
Genotypes
 GG, (%)15 (38.5)40 (51.9)
 GT, (%)19 (48.7)29 (37.7)0.39
 TT, (%)5 (12.8)8 (10.4)
Allele
 T, (%)49 (62.8)45 (29.2)<0.001
 G, (%)29 (37.2)109 (70.8)<0.001
EDSS: Expanded Disability Status Scale of Kurtzke for Multiple Sclerosis; IP: index progression (EDSS/disease evolution). For rs10766197 of CYP2R1 gene: GG: wild homozygous; GA: heterozygous; AA: polymorphic homozygous. For rs10877012 of CYP2B1 gene: GG: wild homozygous; GT: heterozygous; TT: polymorphic homozygous. Qualitative variables were expressed as frequency and percentage. Quantitative variables were expressed as median and min-max. Comparisons between medians were performed using Mann–Whitney test. Comparison between proportions was performed using Chi-square test (or Fisher exact test if applicable). values were obtained comparing multiple sclerosis with severe progression versus multiple sclerosis with low progression.